Valuation: Inventiva

Market Cap 952M 1.1B 893M 814M 1.53B 105B 1.56B 10.51B 4.1B 52.48B 4.12B 4.03B 175B P/E 2026 *
-5.46x
P/E 2027 * -5.02x
Enterprise Value 833M 961M 781M 712M 1.34B 91.68B 1.36B 9.19B 3.59B 45.9B 3.61B 3.53B 153B EV / Sales 2026 *
150x
EV / Sales 2027 * 3.29x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 week-4.73%
Current month+6.05%
1 month+5.50%
3 months-15.60%
6 months-23.67%
Current year+2.15%
1 week 3.96
Extreme 3.955
4.32
1 month 3.58
Extreme 3.585
4.32
Current year 2.88
Extreme 2.88
6.2
1 year 2.88
Extreme 2.88
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Tech/Sci/R&D Officer 56 2025-07-29
Director TitleAgeSince
Director/Board Member 76 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap.
1/10/26 Others

Chief Operating Officer

25,000 0.0131%
1/10/26 Others

Executive/Senior Manager

50,000 0.0262%
1/10/26 Others

General Counsel

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-4.73%+14.98%+15.14% 1.1B
+2.07%+13.76%+65.44%+106.53% 71.56B
-1.59%-2.65%+33.49%+62.55% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.67%+1.02%-18.32%-13.84% 23.14B
+0.15%+1.35%+38.91%-20.08% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
Average -0.59%+3.67%+49.25%+183.43% 26.76B
Weighted average by Cap. -0.39%+3.62%+50.54%+162.50%

Financials

2026 *2027 *
Net sales 5.55M 6.41M 5.21M 4.75M 8.93M 612M 9.08M 61.31M 23.94M 306M 24.06M 23.54M 1.02B 117M 135M 110M 100M 189M 12.91B 192M 1.29B 505M 6.46B 508M 497M 21.55B
Net income -152M -175M -143M -130M -245M -16.74B -248M -1.68B -655M -8.38B -659M -644M -27.95B -103M -119M -96.78M -88.24M -166M -11.37B -169M -1.14B -445M -5.69B -447M -437M -18.98B
Net Debt -120M -138M -112M -102M -192M -13.16B -195M -1.32B -515M -6.59B -518M -506M -21.97B -567M -654M -531M -485M -912M -62.41B -926M -6.26B -2.44B -31.24B -2.46B -2.4B -104B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-08-14 4.020 -0.25% 12,635
26-08-13 €4.030 -2.30% 206,152
26-08-12 €4.125 +0.86% 123,809
26-08-11 €4.090 -1.45% 186,420
26-08-10 €4.150 -1.89% 281,550
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.030EUR
Average target price
9.634EUR
Spread / Average Target
+139.07%

Quarterly revenue - Rate of surprise